Company news

CERo Therapeutics Holdings, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

CERo Therapeutics Doses 7th Patient in Phase 1 CER-1236 Trial

November 3, 2026

CERo Therapeutics Announces Activation of the University of California, Davis as a Clinical Trial Site for the Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies

October 26, 2026

SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics’ Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies

October 26, 2026

CERo Therapeutics Announces Activation of Additional Clinical Trial Site for the CERTAIN-T Trial, its Ongoing Phase 1 Clinical Trial of CER-1236 in Hematological Cancers

October 26, 2026

SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies

October 7, 2026

Decks

The 5 newest of 7 decks. Every deck is listed under its year.